FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2532408919> ?p ?o ?g. }

• W2532408919 endingPage "637" @default.
• W2532408919 startingPage "637" @default.
• W2532408919 abstract "Abstract Purpose: Biphosphonates have been approved for the treatment of bone lesions in patients with multiple myeloma. Although these agents are usually well tolerated, osteonecrosis of the jaw (ONJ) has been recently associated with the use of pamidronate and zoledronic acid. Nevertheless, the true incidence of this complication is not clearly defined. Therefore, we studied the incidence, characteristics and risk factors for the development of ONJ among patients with multiple myeloma treated with biphosphonates in our institution. Patients and Methods: One hundred and thirty-seven patients who received biphosphonates (zoledronic acid: 50 pts, pamidronate: 29 patients, bondronate: 2 pts, pamidronate and zoledronic acid: 50 pts, zoledronic acid and bondronate: 5 pts) since January 1995 and had a minimum exposure of 6 months to the drug were included in this analysis. Since the first reports, which associated ONJ with biphosphonate treatment, we prospectively evaluated this complication (first patient diagnosed in July 2003): all patients complaining of symptoms suggestive of ONJ were referred to a maxillofascial surgeon who confirmed the diagnosis and managed the patients for this complication. The medical records of all patients who were included in the analysis were reviewed in order to exclude symptoms and signs of ONJ, which might have not been formally diagnosed. From this retrospective review, no patient with a highly probable diagnosis of ONJ was identified. Results: Ten patients (6.7%) developed ONJ. The median number of treatment cycles and time of exposure to biphosphonates were 26 infusions and 42 months for patients with ONJ compared to19 infusions (p=0.2) and 27 months (p=0.05) for patients with no ONJ. The cumulative hazard of ONJ increased with time to exposure from 0% for exposure 6–12 months to 13% (95% CI: 3–23) for exposure of 5 years. The use of thalidomide was not associated with the development of ONJ. No case of ONJ was observed among patients treated with pamidronate or pamidronate and ibandronate. In patients who received sequential pamidronate and zoledronic acid, all cases of ONJ occurred during the use of zoledronic acid. The cumulative hazard was significantly higher with zoledronic acid compared to pamidronate alone or sequential administration of pamidronate and zoledronic acid (p=0.022). Among the 10 patients, who developed ONJ, 7 had had dental extraction prior to the development of the complication, 2 had dentures and only one had not had either. In spite of the discontinuation of biphosphonate treatment, only one patient experienced improvement of osteonecrosis, in 7 cases it remained stable and in 2 cases osteonecrosis progressed. Conclusions: The use of biphosphonates in patients with multiple myeloma seems to be associated with the development of ONJ. Our cohort study is the first one which provides a fairly accurate estimate of the incidence of documented ONJ after treatment with biphosphonates. Length of exposure and the type of biphosphonate used appear to be the most important risk factor for this complication. The risk of developing osteonecrosis appears to be higher with zoledronic acid than with pamidronate and may be precipitated by dental extraction." @default.
• W2532408919 created "2016-10-28" @default.
• W2532408919 creator A5004781025 @default.
• W2532408919 creator A5023582747 @default.
• W2532408919 creator A5027331582 @default.
• W2532408919 creator A5041347954 @default.
• W2532408919 creator A5044004656 @default.
• W2532408919 creator A5045869380 @default.
• W2532408919 creator A5059125706 @default.
• W2532408919 creator A5087431865 @default.
• W2532408919 date "2005-11-16" @default.
• W2532408919 modified "2023-09-30" @default.
• W2532408919 title "The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate." @default.
• W2532408919 doi "https://doi.org/10.1182/blood.v106.11.637.637" @default.
• W2532408919 hasPublicationYear "2005" @default.
• W2532408919 type Work @default.
• W2532408919 sameAs 2532408919 @default.
• W2532408919 citedByCount "15" @default.
• W2532408919 countsByYear W25324089192014 @default.
• W2532408919 countsByYear W25324089192015 @default.
• W2532408919 countsByYear W25324089192020 @default.
• W2532408919 countsByYear W25324089192023 @default.
• W2532408919 crossrefType "journal-article" @default.
• W2532408919 hasAuthorship W2532408919A5004781025 @default.
• W2532408919 hasAuthorship W2532408919A5023582747 @default.
• W2532408919 hasAuthorship W2532408919A5027331582 @default.
• W2532408919 hasAuthorship W2532408919A5041347954 @default.
• W2532408919 hasAuthorship W2532408919A5044004656 @default.
• W2532408919 hasAuthorship W2532408919A5045869380 @default.
• W2532408919 hasAuthorship W2532408919A5059125706 @default.
• W2532408919 hasAuthorship W2532408919A5087431865 @default.
• W2532408919 hasConcept C120665830 @default.
• W2532408919 hasConcept C121332964 @default.
• W2532408919 hasConcept C126322002 @default.
• W2532408919 hasConcept C141071460 @default.
• W2532408919 hasConcept C195910791 @default.
• W2532408919 hasConcept C2776326535 @default.
• W2532408919 hasConcept C2776364478 @default.
• W2532408919 hasConcept C2776541429 @default.
• W2532408919 hasConcept C2777251235 @default.
• W2532408919 hasConcept C2777556957 @default.
• W2532408919 hasConcept C61511704 @default.
• W2532408919 hasConcept C71924100 @default.
• W2532408919 hasConcept C81182388 @default.
• W2532408919 hasConceptScore W2532408919C120665830 @default.
• W2532408919 hasConceptScore W2532408919C121332964 @default.
• W2532408919 hasConceptScore W2532408919C126322002 @default.
• W2532408919 hasConceptScore W2532408919C141071460 @default.
• W2532408919 hasConceptScore W2532408919C195910791 @default.
• W2532408919 hasConceptScore W2532408919C2776326535 @default.
• W2532408919 hasConceptScore W2532408919C2776364478 @default.
• W2532408919 hasConceptScore W2532408919C2776541429 @default.
• W2532408919 hasConceptScore W2532408919C2777251235 @default.
• W2532408919 hasConceptScore W2532408919C2777556957 @default.
• W2532408919 hasConceptScore W2532408919C61511704 @default.
• W2532408919 hasConceptScore W2532408919C71924100 @default.
• W2532408919 hasConceptScore W2532408919C81182388 @default.
• W2532408919 hasIssue "11" @default.
• W2532408919 hasLocation W25324089191 @default.
• W2532408919 hasOpenAccess W2532408919 @default.
• W2532408919 hasPrimaryLocation W25324089191 @default.
• W2532408919 hasRelatedWork W2049848179 @default.
• W2532408919 hasRelatedWork W2078823600 @default.
• W2532408919 hasRelatedWork W2129227047 @default.
• W2532408919 hasRelatedWork W2131007572 @default.
• W2532408919 hasRelatedWork W2189375897 @default.
• W2532408919 hasRelatedWork W2297653040 @default.
• W2532408919 hasRelatedWork W2333447821 @default.
• W2532408919 hasRelatedWork W2363563214 @default.
• W2532408919 hasRelatedWork W2405383550 @default.
• W2532408919 hasRelatedWork W4226070154 @default.
• W2532408919 hasVolume "106" @default.
• W2532408919 isParatext "false" @default.
• W2532408919 isRetracted "false" @default.
• W2532408919 magId "2532408919" @default.
• W2532408919 workType "article" @default.